REVIEW ARTICLE
Effects of incretins on blood pressure: A promising therapy for type 2 diabetes mellitus with hypertension
Bin WANG, Yinxing NI,
Jian ZHONG,
Fang SUN,
Yinxing NI
Department of Hypertension and Endocrinology, Daping Hospital, Third Military Medical University, Chongqing, China
Search for more papers by this authorJian ZHONG
Department of Hypertension and Endocrinology, Daping Hospital, Third Military Medical University, Chongqing, China
Search for more papers by this authorFang SUN
Department of Hypertension and Endocrinology, Daping Hospital, Third Military Medical University, Chongqing, China
Search for more papers by this authorBin WANG, Yinxing NI,
Jian ZHONG,
Fang SUN,
Yinxing NI
Department of Hypertension and Endocrinology, Daping Hospital, Third Military Medical University, Chongqing, China
Search for more papers by this authorJian ZHONG
Department of Hypertension and Endocrinology, Daping Hospital, Third Military Medical University, Chongqing, China
Search for more papers by this authorFang SUN
Department of Hypertension and Endocrinology, Daping Hospital, Third Military Medical University, Chongqing, China
Search for more papers by this authorYinxing Ni, Department of Hypertension and Endocrinology, Daping Hospital, Third Military Medical University, Chongqing 400042, China. Tel: +86 023 6875 7882 Fax: +86 023 6875 7882 Email: [email protected]
Abstract
The prevalence of type 2 diabetes mellitus (T2DM) has increased markedly worldwide. A recent epidemiological study reported that approximately 63% of T2DM patients also have high blood pressure (>130/80 mmHg), which doubles their risk of cardiac events. Of the medications used to treat T2DM, the incretins are a group of peptides that not only regulate blood glucose effectively and moderately, but also protect patients against cardiovascular events and improve several cardiovascular parameters. Here were review data from preclinical and short- and long-term clinical studies investigating the antihypertensive effects of incretins. We also elucidate four possible mechanisms underlying the antihypertensive effects of incretins. We conclude that incretins can lower blood pressure of T2DM patients, independent of weight loss, and will surely improve the prognosis of these patients.
References
- 1 Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27: 1047–53.
- 2 Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004; 291: 335–42.
- 3 Grundy SM, Benjamin IJ, Burke GL et al. Diabetes and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation. 1999; 100: 1134–46.
- 4 Patel A, for the ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet. 2007; 370: 829–40.
- 5 Espeland M, Pi-Sunyer X, Blackburn G et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: One-year results of the look AHEAD trial. Diabetes Care. 2007; 30: 1374–83.
- 6 American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003; 26(Suppl.): S80–2.
- 7 Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: A meta-analysis of randomized controlled trials. Hypertension. 2003; 42: 878–84.
- 8 UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998; 317: 703–13.
- 9 Adler AI, Stratton IM, Neil HA et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study. BMJ. 2000; 321: 412–9.
- 10 Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360: 1903–13.
- 11 Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE sub-study. Lancet. 2000; 355: 253–9.
- 12 Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1[7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993; 91: 301–7.
- 13 Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007; 132: 2131–57.
- 14 Vilsbøll T, Zdravkovic M, Le Thi T et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007; 30: 1608–10.
- 15 DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005; 28: 1092–100.
- 16 Herman GA, Stevens C, Van Dyck K et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005; 78: 675–88.
- 17 Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: Vildagliptin (LAF237) dose response. Diabetes Obes Metab. 2005; 7: 692–8.
- 18 Augeri DJ, Robl JA, Betebenner DA et al. Discovery and preclinical profile of saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005; 48: 5025–37.
- 19 Noyan-Ashraf MH, Momen MA, Ban K et al. The GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes following experimental myocardial infarction in mice. Diabetes. 2009; 58: 975–83.
- 20 Noyan-Ashraf H, Ban K, Sadi A-M et al. The GLP-1R agonist liraglutide protects cardiomyocytes and improves survival and cardiac function after experimental murine myocardial infarction. Diabetes. 2008; 57(Suppl. 1): A57 (Abstract).
- 21 Sonne DP, Engstrom T, Treiman M. Protective effects of GLP-1 analogues exendin 4 and GLP-1(9–36) amide against ischemia/reperfusion in rat heart. Regul Pept. 2008; 146: 243–9.
- 22 Poornima I, Brown SB, Bhashyam S, Parikh P, Bolukoglu H, Shannon RP. Chronic glucagon-like peptide-1 infusion sustains left ventricular function and prolongs survival in spontaneously hypertensive, heart failure prone rats. Circ Heart Fail. 2008; 1: 153–60.
- 23 Sokos GG, Bolukoglu H, German J et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol. 2007; 100: 824–9.
- 24 Nikolaidis LA, Elahi D, Hentosz T et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation. 2004; 110: 955–61.
- 25 Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006; 12: 694–9.
- 26 Cervera A, Wajcberg E, Sriwijitkamol A et al. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab. 2008; 294: E846–52.
- 27 Meier JJ, Gethmann A, Götze O et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia. 2006; 49: 452–8.
- 28 Blonde L, Klein EJ, Han J et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006; 8: 436–47.
- 29 Arakawa M, Mita T, Azuma K et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes. 2010; 59: 1030–7.
- 30 Dozier KC, Cureton EL, Kwan RO, Curran B, Sadjadi J, Victorino GP. Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation. Peptides. 2009; 30: 1735–41.
- 31 Simpson RW, Knudsen LB, Liu HB et al. Liraglutide inhibits hyperglycemia induced PAI-1 expression in vascular endothelial cells. Diabetes. 2008; 57(Suppl. 1): A150 (Abstract).
- 32 Courrèges J-P, Vilsbøll T, Zdravkovic M et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes. Diabet Med. 2008; 25: 1129–31.
- 33 Richter G, Feddersen O, Wagner U, Barth P, Göke R, Göke B. GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am J Physiol. 1993; 265: L374–81.
- 34 Golpon HA, Puechner A, Welte T, Wichert PV, Feddersen CO. Vasorelaxant effect of glucagon-like peptide (7–36) amide and amylin on the pulmonary circulation of the rat. Regul Pept. 2001; 102: 81–6.
- 35 Nyström T, Gonon AT, Sjöholm A, Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept. 2005; 125: 173–7.
- 36 Nathanson D, Erdogdu O, Pernow J, Zhang Q, Nyström T. Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo. Regul Pept. 2009; 157: 8–13.
- 37 Yu M, Moreno C, Hoagland KM et al. Antihypertensive effect of glucagon- like peptide 1 in Dahl salt-sensitive rats. J Hypertens. 2003; 21: 1125–35.
- 38 Liu Q, Adams L, Broyde A, Fernandez R, Baron AD, Parkes DG. The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats. Cardiovasc Diabetol. 2010; 9: 32.
- 39 Laugero KD, Stonehouse AH, Guss S, Landry J, Vu C, Parkes DG. Exenatide improves hypertension in a rat model of the metabolic syndrome. Metab Syndr Relat Disord. 2009; 7: 327–34.
- 40 Yamamoto H, Lee CE, Marcus JN et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest. 2002; 110: 43–52.
- 41 Bojanowska E, Stempniak B. Effects of centrally or systemically injected glucagon-like peptide-1 (7–36) amide on release of neurohypophysial hormones and blood pressure in the rat. Regul Pept. 2000; 91: 75–81.
- 42 Isbil-Buyukcoskun N, Gulec G. Effects of intracerebroventricularly injected glucagon-like peptide-1 on cardiovascular parameters; role of central cholinergic system and vasopressin. Regul Pept. 2004; 118: 33–8.
- 43 Nyström T. The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance. Horm Metab Res. 2008; 40: 593–606.
- 44 Apovian CM, Bergenstal RM, Cuddihy RM et al. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med. 2010; 123: 468.
- 45 Mitri J, Hamdy O. Diabetes medications and body weight. Expert Opin Drug Saf. 2009; 8: 573–84.
- 46 Nielsen LL, Okerson T, Holcombe J, Hooqwerf B. Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes. J Diabetes Sci Technol. 2008; 2: 255–60.
- 47 Mudaliar S, Henry RR. Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function. Am J Med. 2010; 123(Suppl.): S19–27.
- 48 Horton ES, Silberman C, Davis KL, Berria R. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care. 2010; 33: 1759–65.
- 49 Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care. 1999; 22: 1137–43.
- 50 Brixner DI, McAdam-Marx C, Ye X et al. Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. Diabetes Obes Metab. 2009; 11: 1122–30.
- 51 Moretto TJ, Milton DR, Ridge TD et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008; 30: 1448–60.
- 52 Astrup A, Rössner S, Van Gaal L et al. Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study. Lancet. 2009; 374: 1606–16.
- 53 Mistry GC, Maes AL, Lasseter KC et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol. 2008; 48: 592–8.
- 54 Buse J, Sesti G, Schmidt WE et al. Switching from twice-daily exenatide to once-daily liraglutide improves glycemic control in T2D on oral agents. Diabetes Care. 2010; 33: 1300–3.
- 55 Assaf-Harofeh Medical Center. The Effect of sitagliptin on hypertension, arterial stiffness, oxidative stress and inflammation (ClinicalTrials.gov identifier NCT00696982). 2008. Available from: http://clinicaltrials.gov/ct2/show/NCT00696982 (accessed 24 December 2010).
- 56 Hannover Medical School. Vascular effects of sitagliptin in diabetes mellitus (ClinicalTrials.gov identifier NCT01096277). 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT01096277 (accessed 24 December 2010).
- 57 Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, Dandona P. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract. 2007; 13: 444–50.
- 58 Bergenstal R, Kim T, Yan P et al. Exenatide once weekly improved cardiometabolic risk factors in subjects with type 2 diabetes during one year of treatment. Diabetologia. 2009; 52(Suppl. 1): S298 (Abstract).
- 59 Okerson T, Yan P, Stonehouse A et al. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens. 2010; 23: 334–9.
- 60 Fonseca V, Madsbad S, Falahati A et al. Once-daily human GLP-1 analog liraglutide reduces systolic BP: A meta-analysis of 6 clinical trials. Diabetes. 2009; 58(Suppl.): A146 (Abstract).
- 61 Buse JB, Drucker DJ, Taylor KL et al. DURATION-1: Exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care. 2010; 33: 1255–61.
- 62 Kim T, Taylor K, Wilhelm K et al. Exenatide once weekly treatment elicits sustained glycemic control and weight loss over 2 years. Diabetes. 2009; 58(Suppl.): 1A.
- 63 Klonoff DC, Buse JB, Nielsen LL et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008; 24: 275–86.
- 64 Gill A, Hoogwerf BJ, Burger J et al. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: A double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol. 2010; 9: 6.
- 65 Buse JB, Henry RR, Han J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004; 27: 2628–35.
- 66 Nyström T, Gutniak MK, Zhang Q et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004; 287: E1209–15.
- 67 Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways. Circulation. 2008; 117: 2340–50.
- 68 Gardiner SM, March JE, Kemp PA, Bennett T. Mesenteric vasoconstriction and hindquarters vasodilation accompany the pressor actions of exendin-4 in conscious rats. J Pharmacol Exp Ther. 2006; 316: 852–9.
- 69 Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006; 368: 1696–705.
- 70 Gutzwiller JP, Hruz P, Huber AR et al. Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans. Digestion. 2006; 73: 142–50.
- 71 Hirata K, Kume S, Araki S et al. Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. Biochem Biophys Res Commun. 2009; 380: 44–9.
Citing Literature
